Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9311705 | 0.85 | PDE4D (0.43) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL127890 | 0.83 | SLC6A3 (0.55) | SLC6A2SLC6A4SLC6A3KCNA5KCNH2 | |
| Water SCHEMBL5164513 | 0.82 | PBRM1 (0.47) | KDM4E | |
| SCHEMBL3952853 | 0.82 | PBRM1 (0.47) | KDM4E | |
| SCHEMBL6344248 | 0.81 | CYP19A1 (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL8317214 | 0.81 | PBRM1 (0.42) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL9312096 | 0.79 | ALDH1A1 (0.41) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL12303932 | 0.79 | CYP19A1 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL4452256 | 0.79 | SMN1; SMN2 (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL4452260 | 0.79 | SMN1; SMN2 (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-1874765-B1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | GALAPAGOS SAS (FR) | 2012-03-07 | — | — | EP | disclosed |
| EP-2354137-A1 | Urea derivatives, methods for their manufacture, and uses thereof | Galapagos SAS (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| CN-101238120-A | Urea derivatives, process for their preparation and their use | GALAPAGOS SAS (FR) | 2008-08-06 | — | — | CN | disclosed |
| EP-1874765-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | Proskelia SAS (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | UTS2R, UGP2, SLC14A1 | CFTR 1018/4885SLC6A2 3896/4885SLC6A4 4269/4885 |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | UGP2, UTS2R, UMPS | CFTR 1226/4885SLC6A2 3644/4885SLC6A4 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.